Bank of New York Mellon’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.8M | Buy |
326,761
+15,378
| +5% | +$811K | ﹤0.01% | 1703 |
|
|
2026
Q1 | $14.8M | Buy |
311,383
+429
| +0.1% | +$22.6K | ﹤0.01% | 1700 |
|
|
2025
Q4 | $16.3M | Buy |
310,954
+6,347
| +2% | +$380K | ﹤0.01% | 1648 |
|
|
2025
Q3 | $19.7M | Buy |
304,607
+2,648
| +0.9% | +$152K | ﹤0.01% | 1562 |
|
|
2025
Q2 | $14.7M | Buy |
301,959
+224,257
| +289% | +$8.68M | ﹤0.01% | 1682 |
|
|
2025
Q1 | $2.64M | Buy |
77,702
+1,133
| +1% | +$48K | ﹤0.01% | 2554 |
|
|
2024
Q4 | $3.01M | Buy |
76,569
+1,553
| +2% | +$73.3K | ﹤0.01% | 2566 |
|
|
2024
Q3 | $3.52M | Sell |
75,016
-3,676
| -5% | -$187K | ﹤0.01% | 2469 |
|
|
2024
Q2 | $4.25M | Buy |
78,692
+3,378
| +4% | +$195K | ﹤0.01% | 2410 |
|
|
2024
Q1 | $5.13M | Sell |
75,314
-32,579
| -30% | -$2.33M | ﹤0.01% | 2317 |
|
|
2023
Q4 | $6.75M | Buy |
107,893
+2,478
| +2% | +$137K | ﹤0.01% | 2218 |
|
|
2023
Q3 | $4.78M | Sell |
105,415
-2,670
| -2% | -$138K | ﹤0.01% | 2343 |
|
|
2023
Q2 | $6.07M | Sell |
108,085
-772
| -0.7% | -$43.8K | ﹤0.01% | 2216 |
|
|
2023
Q1 | $4.92M | Sell |
108,857
-50
| -0% | -$2.43K | ﹤0.01% | 2303 |
|
|
2022
Q4 | $4.43M | Sell |
108,907
-9,537
| -8% | -$506K | ﹤0.01% | 2409 |
|
|
2022
Q3 | $7.74M | Buy |
118,444
+16,669
| +16% | +$1.21M | ﹤0.01% | 2054 |
|
|
2022
Q2 | $6.18M | Buy |
101,775
+10,713
| +12% | +$630K | ﹤0.01% | 2206 |
|
|
2022
Q1 | $5.72M | Buy |
91,062
+26,358
| +41% | +$1.66M | ﹤0.01% | 2347 |
|
|
2021
Q4 | $4.9M | Buy |
64,704
+2,636
| +4% | +$230K | ﹤0.01% | 2475 |
|
|
2021
Q3 | $6.95M | Buy |
62,068
+762
| +1% | +$95.7K | ﹤0.01% | 2326 |
|
|
2021
Q2 | $9.93M | Buy |
61,306
+16,369
| +36% | +$1.99M | ﹤0.01% | 2137 |
|
|
2021
Q1 | $5.47M | Buy |
44,937
+5,090
| +13% | +$769K | ﹤0.01% | 2412 |
|
|
2020
Q4 | $6.1M | Sell |
39,847
-200,056
| -83% | -$23.6M | ﹤0.01% | 2262 |
|
|
2020
Q3 | $20.1M | Buy |
239,903
+16,118
| +7% | +$1.43M | 0.01% | 1474 |
|
|
2020
Q2 | $16.4M | Buy |
223,785
+14,354
| +7% | +$839K | ﹤0.01% | 1565 |
|
|
2020
Q1 | $8.88M | Buy |
209,431
+163,264
| +354% | +$8.43M | ﹤0.01% | 1762 |
|
|
2019
Q4 | $2.81M | Buy |
46,167
+6,736
| +17% | +$368K | ﹤0.01% | 2621 |
|
|
2019
Q3 | $1.61M | Buy |
39,431
+6,340
| +19% | +$303K | ﹤0.01% | 2870 |
|
|
2019
Q2 | $1.56M | Buy |
33,091
+17,810
| +117% | +$712K | ﹤0.01% | 2949 |
|
|
2019
Q1 | $546K | Sell |
15,281
-1,970
| -11% | -$68.1K | ﹤0.01% | 3509 |
|
|
2018
Q4 | $493K | Sell |
17,251
-17,367
| -50% | -$604K | ﹤0.01% | 3490 |
|
|
2018
Q3 | $1.53M | Buy |
34,618
+3,514
| +11% | +$184K | ﹤0.01% | 3009 |
|
|
2018
Q2 | $1.83M | Buy |
31,104
+9,326
| +43% | +$531K | ﹤0.01% | 2900 |
|
|
2018
Q1 | $995K | Buy |
+21,778
| New | +$899K | ﹤0.01% | 3225 |
|
|
2017
Q4 | – | Sell |
-16,132
| Closed | -$288K | – | 4365 |
|
|
2017
Q3 | $288K | Buy |
+16,132
| New | +$293K | ﹤0.01% | 3770 |
|
Other funds holding CRSP
IEFM
PAG
Bank of New York Mellon's CRSP Position: Q2 2026 in Review
Bank of New York Mellon increased its CRISPR Therapeutics (CRSP) stake by 4.9% in Q2 2026, buying an estimated $811K and bringing the position to 326,761 shares worth $17.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1703.
Bank of New York Mellon first reported a position in CRSP in Q3 2017 and has held it in 35 quarters since. The position peaked at $20.1M in Q3 2020. 252 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- Bank of New York Mellon held 326,761 shares of CRISPR Therapeutics worth $17.8M as of Q2 2026.
- Bank of New York Mellon bought 15,378 CRISPR Therapeutics shares in Q2 2026, an estimated $811K.
- CRISPR Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1703 holding.
- Bank of New York Mellon first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 35 quarters since.
- Bank of New York Mellon's CRISPR Therapeutics position peaked at $20.1M in Q3 2020.
- 252 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.